ClinicalTrials.Veeva

Menu

Study of Metabolic Dysfunction-Associated Steatotic Liver Disease Among Sohag University Employees

S

Sohag University

Status

Not yet enrolling

Conditions

Metabolic Dysfunction-Associated Steatotic Liver Disease

Treatments

Diagnostic Test: Abdominal Ultrasound

Study type

Observational

Funder types

Other

Identifiers

NCT06536933
Soh-Med-24-07-19MS

Details and patient eligibility

About

  • Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for steatotic liver disease associated with metabolic syndrome. MASLD is a common cause of chronic liver disease and is the leading cause of liver-related morbidity and mortality.
  • The high prevalence of this disease has been fueled by the rapid rise in levels of sedentary behavior, low levels of physical activity, excess calorie intake relative to expenditure in nutritionally imbalanced and unhealthy diets. In parallel, the prevalence of poor metabolic health in adults from many countries is high, even in normal weight individuals.
  • MASLD has been estimated to affect 30% of the adult population worldwide, with its prevalence increasing from 22% to 37% from 1991 to 2019 . The increasing prevalence of MASLD parallels the increasing prevalence of obesity and obesity-related diseases.

Enrollment

100 estimated patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 100 Employees in Sohag University will be included in the study.

Exclusion criteria

Employees with drug induced liver disease. Employees with chronic liver disease. Employees with decompensated liver cirrhosis. Employees with excessive alcohol consumption.

Trial contacts and locations

1

Loading...

Central trial contact

Ali T A, professor; Hossam Eldin H H, resident

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems